Display options
Cite
Sun X, Tan J, Sun H, et al. Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome. J Clin Neurol. 2020;16(4):530-546doi: 10.3988/jcn.2020.16.4.530.
Sun, X., Tan, J., Sun, H., Liu, Y., Guan, W., Jia, J., & Wang, Z. (2020). Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome. Journal of clinical neurology (Seoul, Korea), 16(4), 530-546. https://doi.org/10.3988/jcn.2020.16.4.530
Sun, Xuan, et al. "Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome." Journal of clinical neurology (Seoul, Korea) vol. 16,4 (2020): 530-546. doi: https://doi.org/10.3988/jcn.2020.16.4.530
Sun X, Tan J, Sun H, Liu Y, Guan W, Jia J, Wang Z. Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome. J Clin Neurol. 2020 Oct;16(4):530-546. doi: 10.3988/jcn.2020.16.4.530. PMID: 33029958; PMCID: PMC7541980.
Copy Download .nbib Format: NLM
Share it on

J Clin Neurol. 2020 Oct;16(4):530-546. doi: 10.3988/jcn.2020.16.4.530.

Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome.

Journal of clinical neurology (Seoul, Korea)

Xuan Sun, Jiping Tan, Hui Sun, Yan Liu, Weiping Guan, Jianjun Jia, Zhenfu Wang

Affiliations

  1. Geriatric Neurological Department of the Second Medical Centre, National Clinical Research Center of Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.
  2. Department of Neurology, the First Medical Centre, Chinese PLA General Hospital, Beijing, China.
  3. Geriatric Neurological Department of the Second Medical Centre, National Clinical Research Center of Geriatric Diseases, Chinese PLA General Hospital, Beijing, China. [email protected].

PMID: 33029958 PMCID: PMC7541980 DOI: 10.3988/jcn.2020.16.4.530

Abstract

Anti-Sry-like high mobility group box (SOX) 1 antibodies (abs) are partly characterized onconeural autoantibodies (autoabs) due to their correlation with neoplastic diseases. Anti-SOX1 abs are associated with various clinical manifestations, including Lambert-Eaton myasthenic syndrome (LEMS) and paraneoplastic cerebellar degeneration (PCD). However, the clinical characteristics of patients with anti-SOX1 abs have not been described in detail. This review systematically explores the reported patients with anti-SOX1 abs and analyzes these cases for demographic characteristics, clinical features, coexisting neuronal autoabs, neuroimaging findings, treatment, and clinical outcomes. In addition, considering that PCD is the most common paraneoplastic neurological syndrome and that the association between PCD and anti-SOX1 abs remains unclear, we focus on the presence of autoabs in relation to PCD and associated tumors. PCD-associated autoabs include various intracellular autoabs (e.g., anti-Hu, anti-Yo, anti-Ri, and anti-SOX1) and cell-surface autoabs (anti-P/Q-type voltage-gated calcium channel). Commonly involved tumors in PCD are small-cell lung cancer (SCLC), gynecological, and breast tumors. LEMS is the most common clinical symptom in patients with anti-SOX1 abs, followed by PCD, and multiple neuronal autoabs coexist in 47.1% of these patients. SCLC is still the predominant tumor in patients with anti-SOX1 abs, while non-SCLC is uncommon. No consistent imaging feature is found in patients with anti-SOX1 abs, and there is no consensus on either the therapy choice or therapeutic efficacy. In conclusion, the presence of anti-SOX1 abs alone is a potential predictor of an uncommon paraneoplastic neurological disorder, usually occurring in the setting of LEMS, PCD, and SCLC. The detection of anti-SOX1 abs contributes to an early diagnosis of underlying tumors, given the diversity of clinical symptoms and the absence of characteristic neuroimaging features.

Copyright © 2020 Korean Neurological Association.

Keywords: SOXB1 transcription factors; antibodies; carcinoma; non-small-cell lung; paraneoplastic cerebellar degeneration; small cell lung carcinoma

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

References

  1. J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):562-3 - PubMed
  2. Curr Neuropharmacol. 2019;17(1):33-58 - PubMed
  3. J Neurol Sci. 2011 Sep 15;308(1-2):139-41 - PubMed
  4. Neurology. 2015 Jun 16;84(24):2403-12 - PubMed
  5. Jpn J Clin Oncol. 2013 May;43(5):563-8 - PubMed
  6. Neurology. 2013 Sep 3;81(10):882-7 - PubMed
  7. Med Clin (Barc). 2016 Nov 18;147(10):e55-e56 - PubMed
  8. J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135-40 - PubMed
  9. BMJ Case Rep. 2019 Jul 16;12(7): - PubMed
  10. Brain. 2003 Jun;126(Pt 6):1409-18 - PubMed
  11. Lung Cancer. 2017 Apr;106:83-92 - PubMed
  12. Acta Neurol Scand. 2012 May;125(5):326-31 - PubMed
  13. Neurol Sci. 2020 May;41(5):1277-1279 - PubMed
  14. Handb Clin Neurol. 2012;103:189-99 - PubMed
  15. J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):412-6 - PubMed
  16. Clin Neurol Neurosurg. 2003 Dec;106(1):47-9 - PubMed
  17. Ann Clin Transl Neurol. 2016 Jun 30;3(8):655-63 - PubMed
  18. Clin Neurol Neurosurg. 2008 Dec;110(10):1044-6 - PubMed
  19. Thorac Cancer. 2019 Apr;10(4):1001-1004 - PubMed
  20. BMC Neurol. 2019 Nov 6;19(1):273 - PubMed
  21. Case Rep Neurol Med. 2013;2013:725936 - PubMed
  22. World J Clin Oncol. 2014 Aug 10;5(3):197-223 - PubMed
  23. Cerebellum Ataxias. 2015 Nov 10;2:14 - PubMed
  24. J Clin Oncol. 2011 Mar 1;29(7):902-8 - PubMed
  25. Arch Neurol. 1998 Mar;55(3):405-8 - PubMed
  26. N Engl J Med. 2000 Jan 6;342(1):21-7 - PubMed
  27. Lancet Neurol. 2008 Apr;7(4):327-40 - PubMed
  28. Curr Oncol. 2018 Dec;25(6):e585-e591 - PubMed
  29. Oncoimmunology. 2017 Nov 27;7(2):e1395125 - PubMed
  30. Arch Neurol. 2010 Mar;67(3):330-5 - PubMed
  31. J Neurol Neurosurg Psychiatry. 1993 Jun;56(6):713-6 - PubMed
  32. BMC Neurol. 2018 Nov 10;18(1):189 - PubMed
  33. Neurol India. 2017 Sep-Oct;65(5):1127-1128 - PubMed
  34. Eur J Paediatr Neurol. 2017 Jul;21(4):661-665 - PubMed
  35. Neurol Sci. 2017 Oct;38(Suppl 2):237-242 - PubMed
  36. Neurology. 2002 Sep 10;59(5):764-6 - PubMed
  37. Dev Cell. 2002 Aug;3(2):167-70 - PubMed
  38. J Neurol Sci. 2016 Oct 15;369:342-346 - PubMed
  39. Cerebellum Ataxias. 2017 Sep 21;4:16 - PubMed
  40. Thorac Cancer. 2020 Feb;11(2):465-469 - PubMed
  41. J Neuroimmunol. 2010 Sep 14;226(1-2):177-80 - PubMed
  42. Tumour Biol. 2015 Jun;36(6):4603-10 - PubMed
  43. Cancer. 2005 Jun 15;103(12):2575-83 - PubMed
  44. BMC Cancer. 2015 Dec 22;15:996 - PubMed
  45. J Neuroimmunol. 2016 Jan 15;290:119-22 - PubMed
  46. Lancet Neurol. 2010 Jan;9(1):67-76 - PubMed
  47. J Clin Neurol. 2019 Oct;15(4):564-565 - PubMed
  48. Eur J Neurol. 2014 May;21(5):731-5 - PubMed
  49. J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):525-8 - PubMed
  50. Neurol Sci. 2015 Aug;36(8):1501-3 - PubMed
  51. J Neuroimmunol. 2008 Sep 15;201-202:163-5 - PubMed
  52. Neurology. 2011 Mar 1;76(9):795-800 - PubMed
  53. Neurohospitalist. 2019 Jul;9(3):165-168 - PubMed
  54. Acta Neuropathol. 2011 Oct;122(4):381-400 - PubMed
  55. J Neuroimmunol. 2005 Aug;165(1-2):166-71 - PubMed
  56. Clin Cancer Res. 2014 Jul 15;20(14):3862-9 - PubMed
  57. Clin Neurol Neurosurg. 2006 Jun;108(4):415-7 - PubMed
  58. Ann Neurol. 2001 Feb;49(2):253-7 - PubMed
  59. Neurosci Lett. 2009 Jan 30;450(2):114-6 - PubMed
  60. Nucleic Acids Res. 1999 Mar 15;27(6):1409-20 - PubMed
  61. Arch Ital Biol. 2011 Sep;149(3):318-22 - PubMed
  62. J Neurol Neurosurg Psychiatry. 2006 Dec;77(12):1359-62 - PubMed
  63. J Neurol Neurosurg Psychiatry. 2015 Sep;86(9):965-72 - PubMed
  64. J Clin Oncol. 2009 Sep 10;27(26):4260-7 - PubMed
  65. J Clin Neurosci. 2013 Oct;20(10):1448-9 - PubMed
  66. Neurology. 2008 Mar 18;70(12):924-8 - PubMed
  67. J Neurol. 2016 May;263(5):1001-1007 - PubMed
  68. Mamm Genome. 1997;8(11):866-8 - PubMed
  69. Cell Res. 2009 Dec;19(12):1324-33 - PubMed
  70. Dig Surg. 2007;24(5):395-7 - PubMed
  71. Rev Med Interne. 2014 Nov;35(11):757-9 - PubMed
  72. Ann N Y Acad Sci. 2012 Dec;1275:70-7 - PubMed
  73. J Neurol Neurosurg Psychiatry. 2007 Feb;78(2):204-5 - PubMed
  74. Neurology. 2013 Oct 22;81(17):1500-6 - PubMed
  75. Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4198-203 - PubMed
  76. Neurology. 2004 Mar 9;62(5):778-82 - PubMed
  77. J Neurol Sci. 2001 Apr 1;185(2):135-8 - PubMed
  78. Immunity. 2013 Jul 25;39(1):1-10 - PubMed
  79. J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):775-7 - PubMed
  80. Neurol Neuroimmunol Neuroinflamm. 2014 Jul 03;1(2):e17 - PubMed
  81. Epigenetics. 2012 Jun 1;7(6):559-66 - PubMed
  82. PLoS One. 2013;8(3):e60438 - PubMed
  83. Curr Oncol Rep. 2018 Nov 10;20(11):92 - PubMed
  84. Intern Med. 2004 Jul;43(7):602-6 - PubMed
  85. Respir Med Case Rep. 2018 Dec 27;26:157-160 - PubMed
  86. N Engl J Med. 2018 Mar 1;378(9):840-851 - PubMed
  87. Neurology. 2008 Sep 16;71(12):930-6 - PubMed
  88. Muscle Nerve. 2017 Nov;56(5):998-1000 - PubMed
  89. Neurology. 2018 Jan 9;90(2):e103-e110 - PubMed
  90. Ann Neurol. 2009 Apr;65(4):424-34 - PubMed
  91. Oxf Med Case Reports. 2018 Jul 09;2018(7):omy034 - PubMed
  92. Front Immunol. 2019 Apr 12;10:769 - PubMed

Publication Types